Zanidatamab plus chemotherapy with or without tislelizumab significantly improves progression free survival in first-line ...
FDA accepted an RTOR sBLA and granted priority review for zanidatamab-hrii combinations as first-line therapy in HER2+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results